Professor Ching-lung LAI is the Emeritus Professor and was the Simon K Y Lee Professor in Gastroenterology and the Chair Professor of Medicine and Hepatology at the Department of Medicine, University of Hong Kong, where he has been working since his graduation with *honors* at the University of Hong Kong since 1971 at the age of 21. For the last five decades he has been extensively involved in research on various aspects of the hepatitis B virus, including molecular virology, natural history, treatment and its prevention. He has received multiple awards by the University of Hong Kong for his outstanding teaching. He is one of the lead investigators in the pivotal trials of various nucleos(t)ide analogues which have revolutionized the treatment of chronic hepatitis B. He is also involved in studies for the treatment of chronic hepatitis C. Recently he has performed some much quoted reviews on COVID-19.

Professor Lai has published over 520 peer-reviewed papers and reviews in international journals as well as book chapters. His publications have been widely cited and he is one of top scientists in the field of chronic hepatitis B infection. He was invited to give the Leon Schiff State-of-the-Art Lecture at the 2005 annual meeting of the American Association for the Study of Liver Diseases (AASLD), entitled "The Natural History and Treatment of Chronic Hepatitis B: Consensus and Controversies". Professor Lai has co-edited a book: "Hepatitis B Virus". Up to October 2023, he has 69,069 citations with an h-index 123 and i10-index 512.

He is one of the co-editors (and co-authors) of the book "Understanding the Pandemic, COVID-19" to be published in 2024 (Elsevier).